Full Breakdown
FDA Proposes Excluding Novo Nordisk and Eli Lilly Weight-Loss Drugs from 503B Bulk Compounding List
5/1/2026, 8:28:57 PM
Regulatory Proposal and Core Details
The FDA announced a proposal to remove three GLP-1 receptor agonists—semaglutide (active in Novo Nordisk’s Wegovy and Ozempic), tirzepatide (Eli Lilly’s Zepbound and Mounjaro), and liraglutide (Novo Nordisk’s older molecule)—from the 503B “bulks” list that permits outsourcing facilities to compound drugs in bulk. The agency said it found no clinical need for such compounding. If adopted, the rule would restrict large-scale production of these weight-loss drugs by outsourcing facilities.
Background: 503B Compounding and GLP-1 Drugs
Section 503B of the Federal Food, Drug, and Cosmetic Act allows FDA-regulated outsourcing facilities to produce compounded medicines in bulk, typically without patient-specific prescriptions. Compounding is permitted only in limited cases, such as drug shortages or non-standard dosages. GLP-1 agents have become blockbuster obesity and diabetes treatments, creating a market for lower-cost compounded versions.
Stakeholders
The FDA is the proposing regulator. Novo Nordisk and Eli Lilly manufacture the targeted drugs. Telehealth firms such as Hims & Hers rely on 503A pharmacies for patient-specific doses and on 503B facilities for bulk supply. Rosalie Hoyle, a research scientist at Avalere, provided an industry perspective.
Data and Timeline
Targeted drugs: semaglutide, tirzepatide, liraglutide. Public comment closes June 29. Current practice: telehealth firms use 503A for individualized doses; 503B for scale. FDA’s finding: no clinical need for bulk compounding.
Official Statements & Responses
The FDA emphasized the lack of a clinical justification for bulk compounding. Eli Lilly’s spokesperson said the proposal confirms there is no basis for compounders to make tirzepatide knockoffs. Novo Nordisk’s spokesperson said the notice reaffirms that compounding should be a rare and limited exception to the FDA’s standard drug-approval framework. Avalere’s Rosalie Hoyle noted the exclusion may not operationally impact current compounding of GLP-1 drugs, because telehealth firms mainly use 503A pharmacies.
Criticism & Industry Concerns
Some observers warn that removing the drugs from the 503B list could curb telehealth firms’ ability to provide affordable compounded versions at scale. Avalere, however, argues the effect may be limited because existing workflows already depend on 503A pharmacies for patient-specific dosing.
Verbatim Quotes
What’s Next
The FDA will consider comments received by June 29 before issuing a final ruling. The decision will determine whether outsourcing facilities may continue bulk compounding of semaglutide, tirzepatide, and liraglutide and will shape telehealth supply strategies.
